Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?
Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?
复制标题
DOI：
10.1016/j.rmcr.2023.101857
复制
发表时间：
2023
影响因子：
1.1
通讯作者：
Yamaguchi, Etsuro
中科院分区：
文献类型：
--
作者：
Yonezawa, Toshiyuki;Suzuki, Atsushi;Fukumitsu, Kensuke;Katano, Takuma;Kako, Hisashi;Ishii, Makoto;Niimi, Akio;Imaizumi, Kazuyoshi;Sakamoto, Koji;Omote, Norihito;Yamaguchi, Etsuro
我们报告一例79岁女性，患有类风湿性关节炎相关间质性肺疾病(RA-ILD)，发展为由冠状病毒病2019年(新冠肺炎)引发的急性加重(AE)。患者对瑞希韦、地塞米松和托西珠单抗联合治疗无效。鉴于最近的一项多中心队列研究报告ILD是RA和新冠肺炎患者预后较差的因素，可能有一定数量的RA-ILD患者由新冠肺炎触发。这一案例突出了讨论如何在日常临床实践中治疗这些患者的必要性。
We present a case of 79-year-old female with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) developed an acute exacerbation (AE) triggered by coronavirus disease 2019 (COVID-19). The patient was unresponsive to a combination therapy of remdesivir, dexamethasone, and tocilizumab. Given that a recent multicenter cohort study reported ILD as a poor prognostic contributor in patients with RA and COVID-19, there may be potentially a certain number of patients with AE of RA-ILD triggered by COVID-19. This case highlights the need for a discussion how to treat these patients in a daily clinical practice.
登录
查看更多内容
影响因子：
3.9
作者：
Torun S;Karaman I
通讯作者：
Karaman I
影响因子：
6.9
作者：
Suzuki, Atsushi;Kondoh, Yasuhiro;Hasegawa, Yoshinori
通讯作者：
Hasegawa, Yoshinori
影响因子：
4.3
作者：
Otsuka, Junji;Yoshizawa, Shigeru;Yoshida, Makoto
通讯作者：
Yoshida, Makoto
影响因子：
13.3
作者：
Mikuls, Ted R.;Johnson, Sindhu R.;Saag, Kenneth G.
通讯作者：
Saag, Kenneth G.
影响因子：
4
作者：
Akiyama, Mitsuhiro;Kaneko, Yuko;Takeuchi, Tsutomu
通讯作者：
Takeuchi, Tsutomu